TABLE 5.
Treatment | No. of subjects | Avg no. of neutrophils/ml |
% decrease in neutrophils | |
---|---|---|---|---|
Prior to dosing | After 14 days of dosing | |||
Plasmochin | ||||
30 mg | 11 | 4,650 | 2,890 | 38 |
60 mg | 4 | 3,878 | 2,920 | 25 |
90 mg | 12 | 4,762 | 1,714 | 64 |
30 mg plasmochin + atabrine | 6 | 5,093 | 1,493 | 69 |
Adapted from reference 151 with permission of the American Society for Clinical Investigation.